Argus Research Downgrades Moderna(MRNA.US) to Hold Rating
Moderna Analyst Ratings
Argus Research Downgrades Moderna(MRNA.US) to Hold Rating
BofA Securities Initiates Moderna(MRNA.US) With Sell Rating, Announces Target Price $41
Moderna Analyst Ratings
Piper Sandler Maintains Moderna(MRNA.US) With Buy Rating, Maintains Target Price $69
Moderna Analyst Ratings
JPMorgan Adjusts Price Target on Moderna to $45 From $59, Maintains Underweight Rating
Jefferies Downgrades Moderna(MRNA.US) to Hold Rating, Cuts Target Price to $50
Baptista Upgrades Moderna to Buy, Price Target at $48
Berenberg Bank Initiates Moderna(MRNA.US) With Hold Rating, Announces Target Price $42
Berenberg Bank Initiates Moderna(MRNA.US) With Hold Rating, Announces Target Price $42
Piper Sandler Reiterates Overweight on Moderna, Lowers Price Target to $69
Moderna Analyst Ratings
HSBC Upgrades Moderna to Buy From Hold, Adjusts Price Target to $58 From $82
Moderna Analyst Ratings
Wolfe Research Downgrades Moderna(MRNA.US) to Sell Rating, Cuts Target Price to $40
Deutsche Bank Adjusts Price Target on Moderna to $60 From $75, Keeps Hold Rating
A Quick Look at Today's Ratings for Moderna(MRNA.US), With a Forecast Between $60 to $112
Moderna Price Target Cut to $111.00/Share From $125.00 by Barclays